CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country

被引:2
|
作者
Sulaiman, Noor Yuhyi [1 ]
Anuar, Nur Adila [1 ]
Arshad, Normala [1 ]
Cheong, Chin Sum [1 ]
Liong, Chee Chiat [1 ]
Khairullah, Shasha [1 ]
Chin, Edmund Fui Min [1 ]
Bee, Ping Chong [1 ]
Sam, I. Ching [2 ]
Iyadorai, Thevambiga [2 ]
Gan, Gin Gin [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
[2] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia
关键词
Hematopoietic stem cell transplantation; Cytomegalovirus prevalence; Cytomegalovirus infection; Southeast Asia; Malaysia; EARLY CYTOMEGALOVIRUS REACTIVATION; RISK-FACTORS; BLOOD-DONORS; MORTALITY; DISEASE; SEROPREVALENCE; PREVENTION; LEUKEMIA; ERA; DNA;
D O I
10.1007/s12288-023-01655-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13-95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 50 条
  • [31] Clinical Impact and Burden of CMV Infection on the Use of Resources in Allogeneic Hematopoietic Cell Transplantation
    de Miguel, Carlos
    Luis Cruz, Juan
    Francisca Portero, Maria
    Esther Martinez-Munoz, Maria
    Isabel Sanchez-Romero, Maria
    Bautista, Guiomar
    Cabrera, Rafael
    Duarte, Rafael F.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S388 - S388
  • [32] Valganciclovir is safe and effective as pre-emptive treatment for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Pastano, Rocco
    Gigli, Federica
    Andreola, Giovanna
    Calabrese, Liliana
    Peccatori, Fedro
    Martinelli, Giovanni
    [J]. BLOOD, 2006, 108 (11) : 417B - 417B
  • [33] Clinical Efficacy of Letermovir Prophylaxis for CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience
    Satake, Atsushi
    Ichikawa, Jun
    Saito, Ryo
    Konishi, Akiko
    Hotta, Masaaki
    Nakanishi, Takahisa
    Nakaya, Aya
    Fujita, Shinya
    Ito, Tomoki
    Ishii, Kazuyoshi
    Nomura, Shosaku
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 479 - 480
  • [34] Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
    Chemaly, Roy F.
    El Haddad, Lynn
    Winston, Drew J.
    Rowley, Scott D.
    Mulane, Kathleen M.
    Chandrasekar, Pranatharthi
    Avery, Robin K.
    Hari, Parameswaran
    Peggs, Karl S.
    Kumar, Deepali
    Nath, Rajneesh
    Ljungman, Per
    Mossad, Sherif B.
    Dadwal, Sanjeet S.
    Blanchard, Ted
    Shah, Dimpy P.
    Jiang, Ying
    Ariza-Heredia, Ella
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) : 2365 - 2374
  • [35] Phenotypic and Functional Characteristics of NK Cells Associated with CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
    Nakamura, Ryotaro
    Zaia, John A.
    Forman, Stephen J.
    Gallez-hawkins, Ghislaine
    Franck, Anne
    Jeannet, Laetitia
    Li, Xiuli
    Dagis, Andy
    Behrendt, Carolyn
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S154 - S155
  • [36] Cytomegalovirus immunoglobulin therapy for CMV retinitis post hematopoietic stem cell transplantation
    Chiu, Tzu-Yu
    Huang, Min-Yu
    Wu, Horng-Jiun
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2023, 33 (04) : NP101 - NP104
  • [37] Oral valganciclovir as pre-emptive therapy for CMV infection post allogeneic haematopoietic stem cell transplantation
    Busca, A
    Locatelli, F
    Ceretto, C
    Ghisetti, V
    de Fabritiis, P
    Mirabile, M
    Gentile, G
    Falda, M
    [J]. BONE MARROW TRANSPLANTATION, 2006, 37 : S188 - S188
  • [38] Clinical Outcome Associated with Cytomegalovirus (CMV) Infection/Disease in CMV-Seropositive Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation
    De latour, Regis Peffault
    Chevallier, Patrice
    Blaise, Didier
    Clement, Aurore
    Allavoine, Thierry
    Tadmouri, Abir
    Blomkvist, Josefin
    Duhamel, Alain
    Yakoub-Agha, Ibrahim
    [J]. BLOOD, 2018, 132
  • [39] USE OF CMV HYPERIMMUNOGLOBULINS (CYTOTECT) AS PREEMPTIVE TREATMENT OF CMV INFECTION IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE CENTRE EXPERIENCE
    Desnica, Lana
    Durakovic, Nadira
    Peric, Zinaida
    Serventi-Seiwerth, Ranka
    Roncevic, Pavle
    Sertic, Dubravka
    Mikulic, Mirta
    Pulanic, Drazen
    Vrhovac, Radovan
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 430 - 431
  • [40] CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
    Eberhardt, Kirsten Alexandra
    Jung, Verena
    Knops, Elena
    Heger, Eva
    Wirtz, Maike
    Steger, Gertrud
    Kaiser, Rolf
    Affeldt, Patrick
    Holtick, Udo
    Klein, Florian
    Scheid, Christof
    Di Cristanziano, Veronica
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (06) : 639 - 646